<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092728</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0447</org_study_id>
    <secondary_id>NCI-2011-00468</secondary_id>
    <nct_id>NCT01092728</nct_id>
  </id_info>
  <brief_title>Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma</brief_title>
  <official_title>A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare how the drug Sprycel (dasatinib) can&#xD;
      help to control the tumor in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged&#xD;
      Melanoma. The safety of this drug will also be studied.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      1. To compare the biological response of tumors With and Without Resectable Tumors from&#xD;
      patients with acral, or mucosal melanomas after treatment with dasatinib.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To assess the safety and tolerability of dasatinib in this patient population&#xD;
&#xD;
           Completely Resectable Acral, Chronic Sun-damaged (CSD), and Mucosal Melanoma:&#xD;
&#xD;
        2. To assess the median time to recurrence and overall survival of patients with completely&#xD;
           resectable acral, CSD, and mucosal melanoma treated with dasatinib&#xD;
&#xD;
        3. To assess whether FDG-avidity and KIT phosphorylation responses after treatment with&#xD;
           dasatinib predicts prolonged time to recurrence and/or overall survival in patients with&#xD;
           completely resectable acral, CSD, and mucosal melanomas&#xD;
&#xD;
           Not Completely Resectable Acral, CSD, and Mucosal Melanoma:&#xD;
&#xD;
        4. To assess the response rate, progression free survival, and overall survival of patients&#xD;
           with acral, CSD, and mucosal melanoma treated with dasatinib&#xD;
&#xD;
        5. To assess whether FDG-avidity and KIT phosphorylation responses after treatment with&#xD;
           dasatinib predicts response rate, progression free survival, and/or overall survival in&#xD;
           patients with acral, CSD, and mucosal melanomas&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Dasatinib is designed to change the function of genes. By changing the function of these&#xD;
      genes, it may prevent cancer from growing and spreading.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be placed into one of&#xD;
      two groups depending on if the disease can be removed by surgery on or not. Group 1 will be&#xD;
      patients who have melanoma that can be removed by surgery. Group 2 will be patients who have&#xD;
      melanoma that cannot be completely removed by surgery.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      For this study, every 4 weeks is a study &quot;cycle.&quot;&#xD;
&#xD;
      Dasatinib pills will be taken by mouth with a full glass (8 ounces) of water with or without&#xD;
      a meal. The pills should not be crushed or cut, they should be swallowed whole.&#xD;
&#xD;
      If you are in Group 1, you will take 2 dasatinib pills 1 time every day, for 7 days before&#xD;
      your already-scheduled surgery. About 6 weeks after surgery (depending on how long it takes&#xD;
      you to recover) you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles&#xD;
      as long as you tolerate it and the disease does not come back.&#xD;
&#xD;
      If you are in Group 2, you will take 2 dasatinib pills 1 time every day, for 7 days before&#xD;
      your already-scheduled biopsy on Day 8 (+/1 business day) of Cycle 1. Within 5 days after the&#xD;
      biopsy, you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles, as long&#xD;
      as you tolerate it and the disease does not come back.&#xD;
&#xD;
      Both groups will be given a pill chart to fill out at home to record when you take the study&#xD;
      drug, and how many pills you take each time. You will need to bring the pill chart to every&#xD;
      study visit for the study doctor to review. You will also need to bring the pill bottles to&#xD;
      each study visit.&#xD;
&#xD;
      Group 1 Study Visits:&#xD;
&#xD;
      After the screening tests have been complete, and before you start taking the study drug, the&#xD;
      following procedures will be performed:&#xD;
&#xD;
        -  Your weight and vital signs will be measured.&#xD;
&#xD;
        -  You will be asked about any drugs you may be taking.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
      After 7 days of taking the study drug, and before surgery, the following procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking.&#xD;
&#xD;
        -  You will have an ECG to check your heart function.&#xD;
&#xD;
        -  You will have a PET scan to check the status of the disease.&#xD;
&#xD;
      About 6 weeks after surgery, when you begin taking the study drug on Cycle 1, the following&#xD;
      tests and procedures will be performed on Day 1 of each cycle:&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking, and any side effects you may&#xD;
           be experiencing.&#xD;
&#xD;
      On Day 15 of Cycle 1 only, the following tests and procedures will be performed:&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking, and any side effects you may&#xD;
           be experiencing.&#xD;
&#xD;
      Every 12 weeks while you are receiving treatment, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  An ECG will be performed to check your heart function.&#xD;
&#xD;
        -  You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check the&#xD;
           status of the disease.&#xD;
&#xD;
      Group 2 Study Visits:&#xD;
&#xD;
      After the screening tests have been complete, and before you start taking the study drug, the&#xD;
      following procedures will be performed:&#xD;
&#xD;
        -  You will have a measurement of your vital signs including your weight.&#xD;
&#xD;
        -  You will be asked about any drugs you may be taking.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
      After 7 days of taking the study drug, and before the biopsy, the following procedures will&#xD;
      be performed:&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking.&#xD;
&#xD;
        -  You will have an ECG to check your heart function.&#xD;
&#xD;
        -  You will have a PET scan to check the status of the disease.&#xD;
&#xD;
      About 5 days after the biopsy, you will begin taking the study drug again for 3 more weeks to&#xD;
      complete Cycle 1. On Day 15 of Cycle 1 only, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have a physical exam including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking, and any side effects you may&#xD;
           be experiencing.&#xD;
&#xD;
      The following tests and procedures will be performed on Day 1 of each cycle starting with&#xD;
      Cycle 2:&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking, and any side effects you may&#xD;
           be experiencing.&#xD;
&#xD;
      Every 12 weeks while you are receiving treatment, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  An ECG will be performed to check your heart function.&#xD;
&#xD;
        -  You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check on the&#xD;
           status of the disease.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will continue to take the study drug for up to 13 cycles. You will be taken off study&#xD;
      early if you experience intolerable side effects, the disease returns (Group 1 only), the&#xD;
      disease gets worse (Group 2 only), or if the study doctor thinks it is in your best interest.&#xD;
&#xD;
      If you are in Group 2, and you are benefiting from the treatment, you may be allowed to&#xD;
      continue to receive treatment with the study drug after you have completed the 12 study&#xD;
      cycles. The study doctor will discuss this option with you in more detail.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      Within 30 days after the last dose of study drug, you will have an end-of-study visit, at&#xD;
      which the following tests and procedures will be performed:&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
        -  An ECG will be performed to check your heart function.&#xD;
&#xD;
        -  You will have a CT scan or MRI scan of your chest, abdomen, and pelvis performed to&#xD;
           check the status of the disease.&#xD;
&#xD;
        -  You will have a physical exam, including a measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking, and any side effects you may&#xD;
           be experiencing.&#xD;
&#xD;
      Follow-Up Visits:&#xD;
&#xD;
      After your participation on this study is complete, you will have follow-up visit every 3&#xD;
      months and you will be asked about your health status. If you do not come to the hospital for&#xD;
      a regularly scheduled clinic visit, you will receive a follow-up phone call. The phone call&#xD;
      should last about 15 minutes each time.&#xD;
&#xD;
      This is an investigational study. Dasatinib is FDA approved and commercially available for&#xD;
      the treatment of certain types of leukemia. The use of dasatinib to treat acral lentiginous&#xD;
      melanoma, mucosal melanoma, or chronic sun-damaged melanoma is investigational.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biologic Response Evaluation of Tumors With and Without Resectable Tumors</measure>
    <time_frame>Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards</time_frame>
    <description>Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, &gt;/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without &gt;15% increase in tumoral Ki-67 expression or &gt;/=25% decrease in tumoral Ki-67 expression without &gt;15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): &gt;/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image &amp; adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.&#xD;
PR or CR confirmatory disease assessment performed &gt;4 weeks (28 days) after criteria for response first met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years</time_frame>
    <description>Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Group 1: Completely Resectable</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Unresectable</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100 mg daily.</description>
    <arm_group_label>Group 1: Completely Resectable</arm_group_label>
    <arm_group_label>Group 2: Unresectable</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
    <description>Complete surgical resection of tumor(s).</description>
    <arm_group_label>Group 1: Completely Resectable</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have primary, recurrent or metastatic melanoma with one of the following&#xD;
             pathology or characteristics: i) acral lentiginous melanoma ii) mucosal melanoma iii)&#xD;
             any known KIT mutation.&#xD;
&#xD;
          2. (Continued 1) If 20 patients without tumors harboring exon 11 or 13 KIT mutation are&#xD;
             enrolled and treated before the completion of the patient accrual of 30, only those&#xD;
             with tumors harboring exon 11 or 13 KIT mutation will be enrolled. Likewise, if 10&#xD;
             patients with tumors harboring exon 11 or 13 KIT mutation are enrolled and treated&#xD;
             before the completion of the patient accrual of 30, only those without tumors&#xD;
             harboring exon 11 or 13 KIT mutation will then be enrolled.&#xD;
&#xD;
          3. Patients must have measurable disease by 18-Fluoro-deoxyglucose positron emission&#xD;
             tomography (FDG-PET) (with or without computed tomography (CT)) defined as having a&#xD;
             maximum standardized uptake value (SUVmax) of 3 and SUVmax ofat least 2 fold greater&#xD;
             than background.&#xD;
&#xD;
          4. Patients scheduled for FDG-PET should have uptake of the tracer in at least one lesion&#xD;
             (tumor-to-muscle ratio &gt;2) in the baseline PET/CT scan in order to be eligible for the&#xD;
             follow-up FDG PET scans.&#xD;
&#xD;
          5. Patient must have surgically resectable melanoma lesion(s) or biopsiable lesion(s)&#xD;
             which are amenable to 2 separate biopsy procedures by a core needle or excision.&#xD;
&#xD;
          6. Age &gt;/= 18 years.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          8. Adequate Organ Function: a. Total bilirubin &lt; 2.0 times the institutional Upper Limit&#xD;
             of Normal (ULN), b.Hepatic enzymes (aspartate transaminase, alanine transaminase (AST,&#xD;
             ALT) ) &lt;/= 2.5 times the institutional ULN, c. Serum Creatinine &lt; 1.5 time the&#xD;
             institutional ULN, d.Neutrophil count &gt;/= 1500; Platelets &gt;/= 75,000;&#xD;
&#xD;
          9. Ability to take oral medication (dasatinib must be swallowed whole)&#xD;
&#xD;
         10. Concomitant Medications: a. Patient agrees to discontinue St. Johns Wort while&#xD;
             receiving dasatinib therapy (discontinue St. Johns Wort at least 5 days before&#xD;
             starting dasatinib), b.Patient agrees that IV bisphosphonates will be withheld for the&#xD;
             first 8 weeks of dasatinib therapy due to risk of hypocalcemia.&#xD;
&#xD;
         11. Women of childbearing potential (WOCBP) must have: a) A negative serum or urine&#xD;
             pregnancy test (sensitivity 25 IU human chorionic gonadotropin (HCG/L) within 72 hours&#xD;
             prior to the start of study drug administration b) Persons of reproductive potential&#xD;
             must agree to use and utilize an adequate method of contraception throughout treatment&#xD;
             and for at least 4 weeks after study drug is stopped. Prior to study enrollment, women&#xD;
             of childbearing potential must be advised of the importance of avoiding pregnancy&#xD;
             during trial participation and the potential risk factors for an unintentional&#xD;
             pregnancy.&#xD;
&#xD;
         12. Signed written informed consent including a Health Insurance Portability and&#xD;
             Accountability Act (HIPAA) form according to institutional guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No other malignancy which required radiotherapy or systemic treatment within the past&#xD;
             5 years.&#xD;
&#xD;
          2. Concurrent medical condition which may increase the risk of toxicity, including: a.&#xD;
             Pleural or pericardial effusion of any grade.&#xD;
&#xD;
          3. Cardiac Symptoms; any of the following should be considered for exclusion: a.&#xD;
             Uncontrolled angina, congestive heart failure or MI within (6 months), b. Diagnosed&#xD;
             congenital long QT syndrome, c. Any history of clinically significant ventricular&#xD;
             arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de&#xD;
             pointes), d. Prolonged corrected QT interval (QTc) interval on pre-entry&#xD;
             electrocardiogram (&gt; 480 msec) [or &gt; 500 msec for patients with a bundle branch&#xD;
             block]), e. Subjects with hypokalemia or hypomagnesemia if it cannot be corrected&#xD;
             prior to dasatinib administration.&#xD;
&#xD;
          4. History of significant bleeding disorder unrelated to cancer, including: a. Diagnosed&#xD;
             congenital bleeding disorders (e.g., von Willebrand's disease), b. Diagnosed acquired&#xD;
             bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies), c.&#xD;
             Ongoing or recent (&lt;/= 3 months) significant gastrointestinal bleeding.&#xD;
&#xD;
          5. Concomitant Medications, any of the following should be considered for exclusion: a.&#xD;
             Category I drugs that are generally accepted to have a risk of causing Torsades de&#xD;
             Pointes including: (Patients must discontinue drug 7 days prior to starting&#xD;
             dasatinib), I. quinidine, procainamide, disopyramide, II. amiodarone, sotalol,&#xD;
             ibutilide, dofetilide, III. erythromycin, clarithromycin, IV. chlorpromazine,&#xD;
             haloperidol, mesoridazine, thioridazine, pimozide V. cisapride, bepridil, droperidol,&#xD;
             methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine,&#xD;
             sparfloxacin, lidoflazine.&#xD;
&#xD;
          6. Women who: a. are unwilling or unable to use an acceptable method to avoid pregnancy&#xD;
             for the entire study period and for at least 4 weeks after cessation of study drug,&#xD;
             or, b. have a positive pregnancy test at baseline, or, c. are pregnant or&#xD;
             breastfeeding,&#xD;
&#xD;
          7. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious) illness&#xD;
&#xD;
          8. No active, untreated brain metastases. Patients with known brain metastases will be&#xD;
             included if the brain metastases have been treated and stable for at least 3 months&#xD;
             without the use of steroid&#xD;
&#xD;
          9. HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with dasatinib. In addition, these&#xD;
             patients are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy. Appropriate studies will be undertaken in patients&#xD;
             receiving combination antiretroviral therapy when indicated.&#xD;
&#xD;
         10. Patients with melanoma harboring BRAF mutation. If BRAF mutation is not known at the&#xD;
             time of screening, patients will still be eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin B. Kim, MD, BA</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>May 13, 2016</results_first_submitted>
  <results_first_submitted_qc>July 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2016</results_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acral lentiginous melanoma</keyword>
  <keyword>Mucosal melanoma</keyword>
  <keyword>Chronic sun-damaged melanoma</keyword>
  <keyword>Surgically removed tumor</keyword>
  <keyword>biopsied</keyword>
  <keyword>Sprycel</keyword>
  <keyword>Dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 2011 to September 2013. All recruitment was done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>A total of 19 participants were enrolled, out of which 18 participants were included in the analysis and 1 participant was a screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib + Completely Resectable</title>
          <description>Participants will receive Dasatinib 100 mg daily for 7 days. Surgical Tumor Resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
        <group group_id="P2">
          <title>Dasatinib + Unresectable</title>
          <description>Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Concomitant Medications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant was screen-failed prior to study group entry.</population>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib + Completely Resectable</title>
          <description>Participants will receive Dasatinib 100 mg daily for 7 days. Surgical Tumor Resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
        <group group_id="B2">
          <title>Dasatinib + Unresectable</title>
          <description>Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" lower_limit="74" upper_limit="81"/>
                    <measurement group_id="B2" value="66" lower_limit="43" upper_limit="79"/>
                    <measurement group_id="B3" value="71" lower_limit="43" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biologic Response Evaluation of Tumors With and Without Resectable Tumors</title>
        <description>Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, &gt;/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without &gt;15% increase in tumoral Ki-67 expression or &gt;/=25% decrease in tumoral Ki-67 expression without &gt;15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): &gt;/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image &amp; adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.&#xD;
PR or CR confirmatory disease assessment performed &gt;4 weeks (28 days) after criteria for response first met.</description>
        <time_frame>Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards</time_frame>
        <population>Of 4 participants in first arm, none were evaluable for response (1 inevaluable, 2 withdrawals, 1 disease progression); and of the second arm, one was inevaluable (withdrawal).</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib + Completely Resectable</title>
            <description>Participants will receive Dasatinib 100 mg daily for 7 days. Surgical Tumor Resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib + Unresectable</title>
            <description>Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Biologic Response Evaluation of Tumors With and Without Resectable Tumors</title>
          <description>Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, &gt;/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without &gt;15% increase in tumoral Ki-67 expression or &gt;/=25% decrease in tumoral Ki-67 expression without &gt;15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): &gt;/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image &amp; adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.&#xD;
PR or CR confirmatory disease assessment performed &gt;4 weeks (28 days) after criteria for response first met.</description>
          <population>Of 4 participants in first arm, none were evaluable for response (1 inevaluable, 2 withdrawals, 1 disease progression); and of the second arm, one was inevaluable (withdrawal).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Metabolic Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Metabolic Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress.</description>
        <time_frame>Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years</time_frame>
        <population>None of the participants in the Resectable arm were evaluable, and one participant in the second Unresectable arm was inevaluable due to early departure from study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib + Completely Resectable</title>
            <description>Participants will receive Dasatinib 100 mg daily for 7 days. Surgical Tumor Resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib + Unresectable</title>
            <description>Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress.</description>
          <population>None of the participants in the Resectable arm were evaluable, and one participant in the second Unresectable arm was inevaluable due to early departure from study.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.00" lower_limit="0.86" upper_limit="89.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE)s and Serious Adverse Events (SAE)s were collected throughout the study from informed consent until 30 days after study treatment was discontinued. Overall AE collection period: March 11, 2011 to September 09, 2013.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib + Completely Resectable</title>
          <description>Participants will receive Dasatinib 100 mg daily for 7 days. Surgical Tumor Resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
        <group group_id="E2">
          <title>Dasatinib + Unresectable</title>
          <description>Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Serum Potassium Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash Desquamating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Kim, MD/Melanoma Medical Oncology</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>1-877-MDA-6789</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

